Discover the intricacies of small vessel ischemic disease and cerebral amyloid angiopathy (CAA) with expert neurologist Dr. Andreas Charidimou.
We dive into the everyday challenges faced by primary care physicians interpreting MRI results, offering expertise on distinguishing small vessel disease from migraine and demyelinating conditions, all while emphasizing the importance of correlating clinical symptoms with imaging for accurate diagnoses.
Navigating cerebral amyloid angiopathy (CAA) diagnosis, this episode sheds light on the inadequacies of the Boston criteria and the quest for reliable biomarkers. As we explore the importance of accurate CAA identification in the era of anti-amyloid therapies, we also offer insights into managing the blurred lines between transient neurological episodes, TIAs, seizures, and amyloid spells, with a special focus on the role of imaging and the nuanced prescription of anti-epileptic drugs.
Dr. Andreas Charidimou is the recipient of the 2024 Michael S. Pessin Stroke Leadership Prize.
You can find him on X at @a_charidimou
A podcast decoding young brains and behavior in a digital world.
Listen on: Apple Podcasts Spotify
- Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes!
- Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com
- Follow our podcast channel on 𝕏 @neuro_podcast for future news!
- Find me on 𝕏 @DrKentris
The views expressed do not necessarily represent those of any associated organizations. The information in this podcast is for educational and informational purposes only and does not represent specific medical/health advice. Please consult with an appropriate health care professional for any medical/health advice.
